Received Mar 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2E574 | — |
Engerix-B administer to a pregnant patient; This non-serious prospective pregnancy case was reported by a nurse via call center representative and described the occurrence of vaccine exposure during pregnancy in a 24-year-old female patient who received HBV (Engerix B) (batch number 2E574, expiry date 11-AUG-2027) for prophylaxis. On 20-JAN-2026, the patient received Engerix B. On an unknown date, an unknown time after receiving Engerix B, the patient experienced vaccine exposure during pregnancy (Verbatim: Engerix-B administer to a pregnant patient). The outcome of the vaccine exposure during pregnancy was not applicable. Pregnancy exposure: Pregnancy Exposure (Engerix B): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Linked case(s) involving the same patient: US2026AMR031282 Additional Information: GSK Receipt Date: 02-MAR-2026 For tolerance to 2nd dose, refer case US2026AMR031282.